Vir Biotechnology VIR Stock
Vir Biotechnology Price Chart
Vir Biotechnology VIR Financial and Trading Overview
| Vir Biotechnology stock price | 9.78 USD |
| Previous Close | 9.21 USD |
| Open | 9.31 USD |
| Bid | 6.96 USD x 200 |
| Ask | 10 USD x 200 |
| Day's Range | 9.31 - 9.86 USD |
| 52 Week Range | 4.35 - 11.66 USD |
| Volume | 1.73M USD |
| Avg. Volume | 1.84M USD |
| Market Cap | 1.65B USD |
| Beta (5Y Monthly) | 1.591 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.77 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21 USD |
VIR Valuation Measures
| Enterprise Value | 1.22B USD |
| Trailing P/E | N/A |
| Forward P/E | -3.9237711 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.4577327 |
| Price/Book (mrq) | 1.9400913 |
| Enterprise Value/Revenue | 4.008 |
| Enterprise Value/EBITDA | -4.536 |
Trading Information
Vir Biotechnology Stock Price History
| Beta (5Y Monthly) | 1.591 |
| 52-Week Change | 123.28% |
| S&P500 52-Week Change | 18.67% |
| 52 Week High | 11.66 USD |
| 52 Week Low | 4.35 USD |
| 50-Day Moving Average | 9.37 USD |
| 200-Day Moving Average | 8.3 USD |
VIR Share Statistics
| Avg. Volume (3 month) | 1.84M USD |
| Avg. Daily Volume (10-Days) | 1.38M USD |
| Shares Outstanding | 169.22M |
| Float | 129.79M |
| Short Ratio | 12.07 |
| % Held by Insiders | 6.56% |
| % Held by Institutions | 84.25% |
| Shares Short | 19.04M |
| Short % of Float | 11.39% |
| Short % of Shares Outstanding | 11.25% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -83.00000000000000000000000000000000% |
| Operating Margin (ttm) | 30.74% |
| Gross Margin | -59.38% |
| EBITDA Margin | -88.36% |
Management Effectiveness
| Return on Assets (ttm) | -14.51% |
| Return on Equity (ttm) | -26.080% |
Income Statement
| Revenue (ttm) | 303.23M USD |
| Revenue Per Share (ttm) | 2.04 USD |
| Quarterly Revenue Growth (yoy) | 19582.50% |
| Gross Profit (ttm) | -180084992 USD |
| EBITDA | -267958000 USD |
| Net Income Avi to Common (ttm) | -251679008 USD |
| Diluted EPS (ttm) | -1.77 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 532.73M USD |
| Total Cash Per Share (mrq) | 3.15 USD |
| Total Debt (mrq) | 93.27M USD |
| Total Debt/Equity (mrq) | 9.49 USD |
| Current Ratio (mrq) | 6.042 |
| Book Value Per Share (mrq) | 5.041 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -202506000 USD |
| Levered Free Cash Flow (ttm) | -38885876 USD |
Profile of Vir Biotechnology
| Country | United States |
| State | CA |
| City | San Francisco |
| Address | 1800 Owens Street |
| ZIP | 94158 |
| Phone | 415 906 4324 |
| Website | https://www.vir.bio |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 367 |
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Q&A For Vir Biotechnology Stock
What is a current VIR stock price?
Vir Biotechnology VIR stock price today per share is 9.78 USD.
How to purchase Vir Biotechnology stock?
You can buy VIR shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vir Biotechnology?
The stock symbol or ticker of Vir Biotechnology is VIR.
Which industry does the Vir Biotechnology company belong to?
The Vir Biotechnology industry is Biotechnology.
How many shares does Vir Biotechnology have in circulation?
The max supply of Vir Biotechnology shares is 169.22M.
What is Vir Biotechnology Price to Earnings Ratio (PE Ratio)?
Vir Biotechnology PE Ratio is now.
What was Vir Biotechnology earnings per share over the trailing 12 months (TTM)?
Vir Biotechnology EPS is -1.77 USD over the trailing 12 months.
Which sector does the Vir Biotechnology company belong to?
The Vir Biotechnology sector is Healthcare.
Vir Biotechnology VIR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26180.46 USD — |
+0.43
|
6.32B USD — | 26049.3 USD — | 26269.85 USD — | — - | 6.32B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12848.65 USD — |
+0.42
|
— — | 12783.89 USD — | 12893.08 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech US Smart Pharmaceuticals
NQSSPH
US
|
2239.51 USD — |
+1.42
|
— — | 2208.5 USD — | 2252.73 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
4033.9 USD — |
+0.7
|
— — | 4010.38 USD — | 4037.39 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7285.19 USD — |
+1.34
|
— — | 7209.03 USD — | 7347.6 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1367.82 USD — |
+1.36
|
— — | 1351.7 USD — | 1374.29 USD — | — - | — — |
- {{ link.label }} {{link}}
